I kid you not, I was just saying the other day to our team how this would be a really great thing to have (and dreaming about it for much, much longer). Thanks so much for this excellent upgrade!
P
Konstantine Palanski
@palanski
Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
Posts
-
NEW Renewals Management Dashboard -
Emails to HCPs regarding conditional reimbursement recommendations@cl This might be helpful: https://forum.paab.ca/topic/2048/email-update-on-cadth-recommendation?_=1620393473878
-
Disclosure requirements of competitor names/schedulesHi PAAB—could you kindly clarify if the below section of the code applies solely to the manufacturer's product or all products mentioned within an APS? Does this vary if the manufacturer opts to include the brand name of another manufacturer's product within an APS, not just its generic name (assume this is permissible due to an acceptable head-to-head trial)?
2.2 In all APS for pharmaceutical products, the brand or trade name, the non-proprietary or generic name and the Federal drug schedule of the product must appear in juxtaposition at least once within advertising copy and must be in good contrast and be legible. -
Draft Guidance on Burden of Disease Presentations@jennifer-carroll This is an exciting change! I'm sure we're all wondering why the PAAB is evolving its stance on this subject, which has in the past generally been a no-go zone. Could you provide any context?
-
Formulary pieces -
Consumer landing page disclaimer on HCP-facing materialsHi there! I understand there is new a requirement to include a disclaimer when linking to websites that have a consumer-facing landing page from HCP materials (e.g., micetype linked to the site URL that states "The website landing page of drugx.ca is open to the general public." or similar).
Could you help clarify what precipitated this requirement and concern it addresses? Additionally, do URLs that direct HCPs to HCP-only landing pages/content require similar disclaimers?
-
Gating requirements for HCP journalHi @mimic909!
If it's properly gated for HCPs, then yes. You might also find this PAAB forum response helpful as well.